Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation

British Journal of Haematology

Volumn 162, Issue 2, 2013, Pages 147-161

  Campana, Dario ^a   Leung, Wing ^b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Haematopoietic stem cell transplantation; Minimal residual disease

Indexed keywords

BCR ABL 1 PROTEIN; BCR ABL PROTEIN; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOGLOBULIN GENE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE RECEPTOR GENE;

ACUTE LYMPHOBLASTIC LEUKAEMIA; ACUTE MYELOID LEUKAEMIA; HAEMATOPOIETIC STEM CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; TREATMENT OUTCOME;

EID: 84879841453     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12358     Document Type: Review

References (104)

1. Antin, J.H., Childs, R., Filipovich, A.H., Giralt, S., Mackinnon, S., Spitzer, T. & Weisdorf, D. (2001) Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 7, 473-485.
2. Bachanova, V., Burke, M.J., Yohe, S., Cao, Q., Sandhu, K., Singleton, T.P., Brunstein, C.G., Wagner, J.E., Verneris, M.R. & Weisdorf, D.J. (2012) Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. Biology of Blood and Marrow Transplantation, 18, 963-968.
3. Bacher, U., Kern, W., Schoch, C., Schnittger, S., Hiddemann, W. & Haferlach, T. (2006) Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer, 106, 839-847.
4. Bacher, U., Badbaran, A., Fehse, B., Zabelina, T., Zander, A.R. & Kroger, N. (2009) Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. Experimental Hematology, 37, 135-142.
5. Bader, P., Hancock, J., Kreyenberg, H., Goulden, N.J., Niethammer, D., Oakhill, A., Steward, C.G., Handgretinger, R., Beck, J.F. & Klingebiel, T. (2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia, 16, 1668-1672.
6. Bader, P., Kreyenberg, H., Hoelle, W., Dueckers, G., Handgretinger, R., Lang, P., Kremens, B., Dilloo, D., Sykora, K.W., Schrappe, M., Niemeyer, C., Von Stackelberg, A., Gruhn, B., Henze, G., Greil, J., Niethammer, D., Dietz, K., Beck, J.F. & Klingebiel, T. (2004) Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? Journal of Clinical Oncology, 22, 1696-1705.
7. Bader, P., Kreyenberg, H., Henze, G.H., Eckert, C., Reising, M., Willasch, A., Barth, A., Borkhardt, A., Peters, C., Handgretinger, R., Sykora, K.W., Holter, W., Kabisch, H., Klingebiel, T. & von Stackelberg, S.A. (2009) Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of Clinical Oncology, 27, 377-384.
8. Boyd, S.D., Marshall, E.L., Merker, J.D., Maniar, J.M., Zhang, L.N., Sahaf, B., Jones, C.D., Simen, B.B., Hanczaruk, B., Nguyen, K.D., Nadeau, K.C., Egholm, M., Miklos, D.B., Zehnder, J.L. & Fire, A.Z. (2009) Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Science Translational Medicine, 1, 12ra23
9. Bradfield, S.M., Radich, J.P. & Loken, M.R. (2004) Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection. Leukemia, 18, 1156-1158.
10. Brenner, M.K., Rill, D.R., Moen, R.C., Krance, R.A., Mirro, J. Jr, Anderson, W.F. & Ihle, J.N. (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet, 341, 85-86.
11. Bruggemann, M., Schrauder, A., Raff, T., Pfeifer, H., Dworzak, M., Ottmann, O.G., Asnafi, V., Baruchel, A., Bassan, R., Benoit, Y., Biondi, A., Cave, H., Dombret, H., Fielding, A.K., Foa, R., Gokbuget, N., Goldstone, A.H., Goulden, N., Henze, G., Hoelzer, D., Janka-Schaub, G.E., Macintyre, E.A., Pieters, R., Rambaldi, A., Ribera, J.M., Schmiegelow, K., Spinelli, O., Stary, J., von Stackelberg, A., Kneba, M., Schrappe, M. & van Dongen, J.J. (2010) Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia, 24, 521-535.
12. Buccisano, F., Maurillo, L., Del Principe, M.I., Del Poeta, G., Sconocchia, G., Lo-Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2012) Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, 119, 332-341.
13. Buckley, S.A., Appelbaum, F.R. & Walter, R.B. (2012) Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplantation, doi: 10.1038/bmt.2012.139
14. Campana, D. (2012) Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care? Current Hematologic Malignancy Reports, 7, 170-177.
15. Candoni, A., Toffoletti, E., Gallina, R., Simeone, E., Chiozzotto, M., Volpetti, S. & Fanin, R. (2011) Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clinical Transplantation, 25, 308-316.
16. Chan, W.K., Kung Sutherland, M., Li, Y., Zalevsky, J., Schell, S. & Leung, W. (2012) Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Clinical Cancer Research, 18, 6296-6305.
17. Chang, Y.H., Connolly, J., Shimasaki, N., Mimura, K., Kono, K. & Campana, D. (2013) A chimeric receptor with Nkg2d specificity enhances natural killer cell activation and killing of tumor cells. Cancer Research, 73, 1777-1786.
18. Chen, Y., Cortes, J., Estrov, Z., Faderl, S., Qiao, W., Abruzzo, L., Garcia-Manero, G., Pierce, S., Huang, X., Kebriaei, P., Kadia, T., De Lima, M., Kantarjian, H. & Ravandi, F. (2011) Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. Journal of Clinical Oncology, 29, 2507-2513.
19. Cooley, S., Weisdorf, D.J., Guethlein, L.A., Klein, J.P., Wang, T., Le, C.T., Marsh, S.G., Geraghty, D., Spellman, S., Haagenson, M.D., Ladner, M., Trachtenberg, E., Parham, P. & Miller, J.S. (2010) Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood, 116, 2411-2419.
20. Coustan-Smith, E., Sancho, J., Hancock, M.L., Boyett, J.M., Behm, F.G., Raimondi, S.C., Sandlund, J.T., Rivera, G.K., Rubnitz, J.E., Ribeiro, R.C., Pui, C.H. & Campana, D. (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood, 96, 2691-2696.
21. Coustan-Smith, E., Ribeiro, R.C., Rubnitz, J.E., Razzouk, B.I., Pui, C.H., Pounds, S., Andreansky, M., Behm, F.G., Raimondi, S.C., Shurtleff, S.A., Downing, J.R. & Campana, D. (2003) Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. British Journal of Haematology, 123, 243-252.
22. Coustan-Smith, E., Song, G., Clark, C., Key, L., Liu, P., Mehrpooya, M., Stow, P., Su, X., Shurtleff, S., Pui, C.H., Downing, J.R. & Campana, D. (2011) New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood, 117, 6267-6276.
23. Diez-Campelo, M., Perez-Simon, J.A., Perez, J., Alcoceba, M., Richtmon, J., Vidriales, B. & San Miguel, J. (2009) Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. American Journal of Hematology, 84, 149-152.
24. Ding, L., Ley, T.J., Larson, D.E., Miller, C.A., Koboldt, D.C., Welch, J.S., Ritchey, J.K., Young, M.A., Lamprecht, T., McLellan, M.D., McMichael, J.F., Wallis, J.W., Lu, C., Shen, D., Harris, C.C., Dooling, D.J., Fulton, R.S., Fulton, L.L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V.J., Cook, L., McGrath, S.D., Vickery, T.L., Wendl, M.C., Heath, S., Watson, M.A., Link, D.C., Tomasson, M.H., Shannon, W.D., Payton, J.E., Kulkarni, S., Westervelt, P., Walter, M.J., Graubert, T.A., Mardis, E.R., Wilson, R.K. & DiPersio, J.F. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 481, 506-510.
25. Dombret, H., Gabert, J., Boiron, J.M., Rigal-Huguet, F., Blaise, D., Thomas, X., Delannoy, A., Buzyn, A., Bilhou-Nabera, C., Cayuela, J.M., Fenaux, P., Bourhis, J.H., Fegueux, N., Charrin, C., Boucheix, C., Lheritier, V., Esperou, H., MacIntyre, E., Vernant, J.P. & Fiere, D. (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood, 100, 2357-2366.
26. Dominietto, A., Pozzi, S., Miglino, M., Albarracin, F., Piaggio, G., Bertolotti, F., Grasso, R., Zupo, S., Raiola, A.M., Gobbi, M., Frassoni, F. & Bacigalupo, A. (2007) Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood, 109, 5063-5064.
27. Elmaagacli, A.H., Beelen, D.W., Kroll, M., Trzensky, S., Stein, C. & Schaefer, U.W. (1998) Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplantation, 21, 159-166.
28. Elmaagacli, A.H., Beelen, D.W., Trenschel, R. & Schaefer, U.W. (2000) The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplantation, 25, 91-96.
29. Elorza, I., Palacio, C., Dapena, J.L., Gallur, L., de Toledo, J.S. & de Heredia, C.D. (2010) Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica, 95, 936-941.
30. Faham, M., Zheng, J., Moorhead, M., Carlton, V.E., Stow, P., Coustan-Smith, E., Pui, C.H. & Campana, D. (2012) Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood, 120, 5173-5180.
31. Feller, N., Jansen-van der Weide, M.C., van der Pol, M.A., Westra, G.A., Ossenkoppele, G.J. & Schuurhuis, G.J. (2005) Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden. Experimental Hematology, 33, 120-130.
32. Formankova, R., Sedlacek, P., Krskova, L., Rihova, H., Sramkova, L. & Star, J. (2003) Chimerism-directed adoptive immunotherapy in prevention and treatment of post-transplant relapse of leukemia in childhood. Haematologica, 88, 117-118.
33. Freireich, E.J., Cork, A., Stass, S.A., McCredie, K.B., Keating, M.J., Estey, E.H., Kantarjian, H.M. & Trujillo, J.M. (1992) Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia, 6, 500-506.
34. Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W.H. & Campana, D. (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Research, 69, 4010-4017.
35. Giebel, S., Locatelli, F., Lamparelli, T., Velardi, A., Davies, S., Frumento, G., Maccario, R., Bonetti, F., Wojnar, J., Martinetti, M., Frassoni, F., Giorgiani, G., Bacigalupo, A. & Holowiecki, J. (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood, 102, 814-819.
36. Giebel, S., Stella-Holowiecka, B., Krawczyk-Kulis, M., Gokbuget, N., Hoelzer, D., Doubek, M., Mayer, J., Piatkowska-Jakubas, B., Skotnicki, A.B., Dombret, H., Ribera, J.M., Piccaluga, P.P., Czerw, T., Kyrcz-Krzemien, S. & Holowiecki, J. (2010) Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL. Bone Marrow Transplantation, 45, 1095-1101.
37. Gokbuget, N., Kneba, M., Raff, T., Trautmann, H., Bartram, C.R., Arnold, R., Fietkau, R., Freund, M., Ganser, A., Ludwig, W.D., Maschmeyer, G., Rieder, H., Schwartz, S., Serve, H., Thiel, E., Bruggemann, M. & Hoelzer, D. (2012) Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood, 120, 1868-1876.
38. Goulden, N. & Steward, C. (2002) Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL. Best Practice & Research. Clinical Haematology, 15, 59-70.
39. Goulden, N., Oakhill, A. & Steward, C. (2001) Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation. British Journal of Haematology, 112, 275-281.
40. Handgretinger, R., Zugmaier, G., Henze, G., Kreyenberg, H., Lang, P. & von Stackelberg, A. (2011) Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia, 25, 181-184.
41. Harris, J. & Freireich, E.J. (1970) In vitro growth of myeloid colonies from bone marrow of patients with acute leukemia in remission. Blood, 35, 61-63.
42. Imai, C., Iwamoto, S. & Campana, D. (2005) Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood, 106, 376-383.
43. Inaba, H., Coustan-Smith, E., Cao, X., Pounds, S.B., Shurtleff, S.A., Wang, K.Y., Raimondi, S.C., Onciu, M., Jacobsen, J., Ribeiro, R.C., Dahl, G.V., Bowman, W.P., Taub, J.W., Degar, B., Leung, W., Downing, J.R., Pui, C.H., Rubnitz, J.E. & Campana, D. (2012a) Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. Journal of Clinical Oncology, 30, 3625-3632.
44. Inaba, H., Bhojwani, D., Pauley, J.L., Pei, D., Cheng, C., Metzger, M.L., Howard, S.C., Rubnitz, J.E., Sandlund, J.T., Ribeiro, R.C., Leung, W., Campana, D., Pui, C.H. & Jeha, S. (2012b) Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. British Journal of Haematology, 156, 275-279.
45. Jacobsohn, D.A., Tse, W.T., Chaleff, S., Rademaker, A., Duerst, R., Olszewski, M., Huang, W., Chou, P.M. & Kletzel, M. (2009) High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. British Journal of Haematology, 146, 669-674.
46. Kanamori, H., Sasaki, S., Yamazaki, E., Ueda, S., Hattori, M., Fukawa, H., Tamura, T., Harano, H., Matsuzaki, M., Ogawa, K., Mohri, H. & Okubo, T. (1997) Eradication of minimal residual disease during graft-versus-host reaction induced by abrupt discontinuation of immunosuppression following bone marrow transplantation in a patient with Ph1-ALL. Transplant International, 10, 328-330.
47. Kern, S.E. (2012) Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Research, 72, 6097-6101.
48. Knechtli, C.J.C., Goulden, N.J., Hancock, J.P., Grandage, V.L.G., Harris, E.L., Garland, R.J., Jones, C.G., Rowbottom, A.W., Hunt, L.P., Green, A.F., Clarke, E., Lankester, A.W., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998a) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92, 4072-4079.
49. Knechtli, C.J., Goulden, N.J., Hancock, J.P., Harris, E.L., Garland, R.J., Jones, C.G., Grandage, V.L., Rowbottom, A.W., Green, A.F., Clarke, E., Lankester, A.W., Potter, M.N., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998b) Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. British Journal of Haematology, 102, 860-871.
50. Kolb, H.J., Schattenberg, A., Goldman, J.M., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L. & Niederwieser, D. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood, 86, 2041-2050.
51. Krejci, O., van der Velden, V., Bader, P., Kreyenberg, H., Goulden, N., Hancock, J., Schilham, M.W., Lankester, A., Revesz, T., Klingebiel, T. & van Dongen, J.J. (2003) Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplantation, 32, 849-851.
52. Kwon, M., Martinez-Laperche, C., Infante, M., Carretero, F., Balsalobre, P., Serrano, D., Gayoso, J., Perez-Corral, A., Anguita, J., Diez-Martin, J.L. & Buno, I. (2012) Evaluation of minimal residual disease by real-time quantitative PCR of Wilms' tumor 1 expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biology of Blood and Marrow Transplantation, 18, 1235-1242.
53. Laane, E., Derolf, A.R., Bjorklund, E., Mazur, J., Everaus, H., Soderhall, S., Bjorkholm, M. & Porwit-MacDonald, A. (2006) The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica, 91, 833-836.
54. Langerak, A.W., Groenen, P.J., Bruggemann, M., Beldjord, K., Bellan, C., Bonello, L., Boone, E., Carter, G.I., Catherwood, M., Davi, F., Delfau-Larue, M.H., Diss, T., Evans, P.A., Gameiro, P., Garcia Sanz, R., Gonzalez, D., Grand, D., Hakansson, A., Hummel, M., Liu, H., Lombardia, L., Macintyre, E.A., Milner, B.J., Montes-Moreno, S., Schuuring, E., Spaargaren, M., Hodges, E. & van Dongen, J.J. (2012) EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia, 26, 2159-2171.
55. Lankester, A.C., Bierings, M.B., Van Wering, E.R., Wijkhuijs, A.J., de Weger, R.A., Wijnen, J.T., Vossen, J.M., Versluys, B., Egeler, R.M., van Tol, M.J., Putter, H., Revesz, T., van Dongen, J.J., van der Velden, V.H. & Schilham, M.W. (2010) Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia, 24, 1462-1469.
56. Lapteva, N., Durett, A.G., Sun, J., Rollins, L.A., Huye, L.L., Fang, J., Dandekar, V., Mei, Z., Jackson, K., Vera, J., Ando, J., Ngo, M.C., Coustan-Smith, E., Campana, D., Szmania, S., Garg, T., Moreno-Bost, A., Vanrhee, F., Gee, A.P. & Rooney, C.M. (2012) Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy, 14, 1131-1143.
57. Lee, S., Kim, D.W., Cho, B.S., Yoon, J.H., Shin, S.H., Yahng, S.A., Lee, S.E., Eom, K.S., Kim, Y.J., Chung, N.G., Kim, H.J., Min, C.K., Lee, J.W., Min, W.S. & Park, C.W. (2012) Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia, 26, 2367-2374.
58. Leung, W., Iyengar, R., Turner, V., Lang, P., Bader, P., Conn, P., Niethammer, D. & Handgretinger, R. (2004) Determinants of antileukemia effects of allogeneic NK cells. Journal of Immunology, 172, 644-650.
59. Leung, W., Campana, D., Yang, J., Pei, D., Coustan-Smith, E., Gan, K., Rubnitz, J.E., Sandlund, J.T., Ribeiro, R.C., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Handgretinger, R., Laver, J.H. & Pui, C.H. (2011) High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood, 118, 223-230.
60. Leung, W., Pui, C.H., Coustan-Smith, E., Yang, J., Pei, D., Gan, K., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Shook, D., Rubnitz, J.E., Sandlund, J.T., Jeha, S., Inaba, H., Ribeiro, R.C., Handgretinger, R., Laver, J.H. & Campana, D. (2012) Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 120, 468-472.
61. Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., Baty, J., Welch, J., Harris, C.C., Lichti, C.F., Townsend, R.R., Fulton, R.S., Dooling, D.J., Koboldt, D.C., Schmidt, H., Zhang, Q., Osborne, J.R., Lin, L., O'Laughlin, M., McMichael, J.F., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Magrini, V.J., Vickery, T.L., Hundal, J., Cook, L.L., Conyers, J.J., Swift, G.W., Reed, J.P., Alldredge, P.A., Wylie, T., Walker, J., Kalicki, J., Watson, M.A., Heath, S., Shannon, W.D., Varghese, N., Nagarajan, R., Westervelt, P., Tomasson, M.H., Link, D.C., Graubert, T.A., DiPersio, J.F., Mardis, E.R. & Wilson, R.K. (2010) DNMT3A mutations in acute myeloid leukemia. New England Journal of Medicine, 363, 2424-2433.
62. Mathe, G., Schwarzenberg, L., Mery, A.M., Cattan, A., Schneider, M., Amiel, J.L., Schlumberger, J.R., Poisson, J. & Wajcner, G. (1966) Extensive histological and cytological survey of patients with acute leukaemia in "complete remission". British Medical Journal, 5488, 640-642.
63. Maurillo, L., Buccisano, F., Del Principe, M.I., Del, P.G., Spagnoli, A., Panetta, P., Ammatuna, E., Neri, B., Ottaviani, L., Sarlo, C., Venditti, D., Quaresima, M., Cerretti, R., Rizzo, M., De Fabritiis, F.P., Lo Coco, F., Arcese, W., Amadori, S. & Venditti, A. (2008) Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. Journal of Clinical Oncology, 26, 4944-4951.
64. Mertelsmann, R., Moore, M.A., Broxmeyer, H.E., Cirrincione, C. & Clarkson, B. (1981) Diagnostic and prognostic significance of the CFU-c assay in acute nonlymphoblastic leukemia. Cancer Research, 41, 4844-4848.
65. Miglino, M., Berisso, G., Grasso, R., Canepa, L., Clavio, M., Pierri, I., Pietrasanta, D., Gatto, S., Varaldo, R., Ballerini, F., Verdiani, S., Casarino, L., DeStefano, F., Sessarego, M., Dominietto, A., Raiola, A.M., Bregante, S., di Grazia, C., Gobbi, M. & Bacigalupo, A. (2002) Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse. Bone Marrow Transplantation, 30, 579-585.
66. Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S.A., Yun, G.H., Fautsch, S.K., McKenna, D., Le, C., Defor, T.E., Burns, L.J., Orchard, P.J., Blazar, B.R., Wagner, J.E., Slungaard, A., Weisdorf, D.J., Okazaki, I.J. & McGlave, P.B. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood, 105, 3051-3057.
67. Miyazaki, T., Fujita, H., Fujimaki, K., Hosoyama, T., Watanabe, R., Tachibana, T., Fujita, A., Matsumoto, K., Tanaka, M., Koharazawa, H., Taguchi, J., Tomita, N., Sakai, R., Fujisawa, S., Kanamori, H. & Ishigatsubo, Y. (2012) Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leukemia Research, 36, 998-1003.
68. Mizuta, S., Ito, Y., Kohno, A., Kiyoi, H., Miyamura, K., Tanimoto, M., Takamatsu, J., Naoe, T., Morishima, Y., Ueda, R. & Saito, H. (1999) Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group. Bone Marrow Transplantation, 24, 777-784.
69. Moore, M.A., Spitzer, G., Williams, N., Metcalf, D. & Buckley, J. (1974) Agar culture studies in 127 cases of untreated acute leukemia: the prognostic value of reclassification of leukemia according to in vitro growth characteristics. Blood, 44, 1-18.
70. Mortuza, F.Y., Papaioannou, M., Moreira, I.M., Coyle, L.A., Gameiro, P., Gandini, D., Prentice, H.G., Goldstone, A., Hoffbrand, A.V. & Foroni, L. (2002) Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. Journal of Clinical Oncology, 20, 1094-1104.
71. Ogawa, H., Tamaki, H., Ikegame, K., Soma, T., Kawakami, M., Tsuboi, A., Kim, E.H., Hosen, N., Murakami, M., Fujioka, T., Masuda, T., Taniguchi, Y., Nishida, S., Oji, Y., Oka, Y. & Sugiyama, H. (2003) The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood, 101, 1698-1704.
72. Ommen, H.B., Schnittger, S., Jovanovic, J.V., Ommen, I.B., Hasle, H., Ostergaard, M., Grimwade, D. & Hokland, P. (2010) Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood, 115, 198-205.
73. Osborne, D., Frost, L., Tobal, K. & Liu Yin, J.A. (2005) Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia. Bone Marrow Transplantation, 36, 67-70.
74. Paganin, M., Zecca, M., Fabbri, G., Polato, K., Biondi, A., Rizzari, C., Locatelli, F. & Basso, G. (2008) Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia, 22, 2193-2200.
75. Patel, B., Rai, L., Buck, G., Richards, S.M., Mortuza, Y., Mitchell, W., Gerrard, G., Moorman, A.V., Duke, V., Hoffbrand, A.V., Fielding, A.K., Goldstone, A.H. & Foroni, L. (2010) Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. British Journal of Haematology, 148, 80-89.
76. Pfeifer, H., Wassmann, B., Bethge, W., Dengler, J., Bornhauser, M., Stadler, M., Beelen, D., Vucinic, V., Burmeister, T., Stelljes, M., Faul, C., Dreger, P., Kiani, A., Schafer-Eckart, K., Schwerdtfeger, R., Lange, E., Kubuschok, B., Horst, H.A., Gramatzki, M., Bruck, P., Serve, H., Hoelzer, D., Gokbuget, N. & Ottmann, O.G. (2012) Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1 positive acute lymphoblastic leukemia. Leukemia, doi: 10.1038/leu.2012.352.
77. Platzbecker, U., Wermke, M., Radke, J., Oelschlaegel, U., Seltmann, F., Kiani, A., Klut, I.M., Knoth, H., Rollig, C., Schetelig, J., Mohr, B., Graehlert, X., Ehninger, G., Bornhauser, M. & Thiede, C. (2012) Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia, 26, 381-389.
78. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New England Journal of Medicine, 365, 725-733.
79. Pui, C.H., Campana, D., Pei, D., Bowman, W.P., Sandlund, J.T., Kaste, S.C., Ribeiro, R.C., Rubnitz, J.E., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Kun, L.E., Jeha, S., Cheng, C., Howard, S.C., Simmons, V., Bayles, A., Metzger, M.L., Boyett, J.M., Leung, W., Handgretinger, R., Downing, J.R., Evans, W.E. & Relling, M.V. (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. New England Journal of Medicine, 360, 2730-2741.
80. Radich, J., Ladne, P. & Gooley, T. (1995) Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT. Biology of Blood and Marrow Transplantation, 1, 24-31.
81. Rettinger, E., Willasch, A.M., Kreyenberg, H., Borkhardt, A., Holter, W., Kremens, B., Strahm, B., Woessmann, W., Mauz-Koerholz, C., Gruhn, B., Burdach, S., Albert, M.H., Schlegel, P.G., Klingebiel, T. & Bader, P. (2011) Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood, 118, 5681-5688.
82. Rubnitz, J.E., Inaba, H., Dahl, G.V., Ribeiro, R.C., Bowman, W.P., Taub, J.W., Pounds, S., Razzouk, B.I., Lacayo, N., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W.H., Pui, C.H. & Campana, D. (2010a) Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicenter trial. The Lancet Oncology, 11, 543-552.
83. Rubnitz, J.E., Inaba, H., Ribeiro, R.C., Pounds, S., Rooney, B., Bell, T., Pui, C.H. & Leung, W. (2010b) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. Journal of Clinical Oncology, 28, 955-959.
84. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W.D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M.F. & Velardi, A. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295, 2097-2100.
85. Ruggeri, A., Michel, G., Dalle, J.H., Caniglia, M., Locatelli, F., Campos, A., de Heredia, C.D., Mohty, M., Hurtado, J.M., Bierings, M., Bittencourt, H., Mauad, M., Purtill, D., Cunha, R., Kabbara, N., Gluckman, E., Labopin, M., Peters, C. & Rocha, V. (2012) Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis. Leukemia, 26, 2455-2461.
86. Rujkijyanont, P., Chan, W.K., Eldridge, P.W., Lockey, T., Holladay, M., Rooney, B., Davidoff, A.M., Leung, W. & Vong, Q. (2013) Ex vivo activation of CD56+ immune cells that eradicate neuroblastoma. Cancer Research, 73, 2608-2618.
87. Sanchez, J., Serrano, J., Gomez, P., Martinez, F., Martin, C., Madero, L., Herrera, C., Garcia, J.M., Casano, J. & Torres, A. (2002) Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. British Journal of Haematology, 116, 686-694.
88. Sanchez-Garcia, J., Serrano, J., Serrano-Lopez, J., Gomez-Garcia, P., Martinez, F., Garcia-Castellano, J.M., Rojas, R., Martin, C., Rodriguez-Villa, A., Molina-Hurtado, J.R., Alvarez, M.A., Casano, J. & Torres-Gomez, A. (2012) Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL. Bone Marrow Transplantation, 48, 396-402.
89. Schneider, M., Hettinger, K., Matthes-Martin, S., Konrad, M., Peters, C., Gadner, H. & Panzer-Grumayer, E.R. (2001) Influence of transplantation regimen on prognostic significance of high-level minimal residual disease before allogeneic stem cell transplantation in children with ALL. Bone Marrow Transplantation, 28, 1087-1089.
90. Shimasaki, N., Fujisaki, H., Cho, D., Masselli, M., Lockey, T., Eldridge, P., Leung, W.H. & Campana, D. (2012) A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy, 14, 830-840.
91. Shook, D., Coustan-Smith, E., Ribeiro, R.C., Rubnitz, J.E. & Campana, D. (2009) Minimal residual disease quantitation in acute myeloid leukemia. Clinical Lymphoma & Myeloma, 9(Suppl. 3), S281-S285.
92. Spinelli, O., Peruta, B., Tosi, M., Guerini, V., Salvi, A., Zanotti, M.C., Oldani, E., Grassi, A., Intermesoli, T., Mico, C., Rossi, G., Fabris, P., Lambertenghi-Deliliers, G., Angelucci, E., Barbui, T., Bassan, R. & Rambaldi, A. (2007) Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica, 92, 612-618.
93. Sramkova, L., Muzikova, K., Fronkova, E., Krejci, O., Sedlacek, P., Formankova, R., Mejstrikova, E., Stary, J. & Trka, J. (2007) Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer, 48, 93-100.
94. Topp, M.S., Kufer, P., Gokbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.A., Raff, T., Viardot, A., Schmid, M., Stelljes, M., Schaich, M., Degenhard, E., Kohne-Volland, R., Bruggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baeuerle, P.A., Kneba, M., Einsele, H., Riethmuller, G., Hoelzer, D., Zugmaier, G. & Bargou, R.C. (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Journal of Clinical Oncology, 29, 2493-2498.
95. Uzunel, M., Jaksch, M., Mattsson, J. & Ringden, O. (2003) Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. British Journal of Haematology, 122, 788-794.
96. van der Velden, V., Joosten, S.A., Willemse, M.J., Van Wering, E.R., Lankester, A.W., van Dongen, J.J. & Hoogerbrugge, P.M. (2001) Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia, 15, 1485-1487.
97. van der Velden, V.H., Sluijs-Geling, A., Gibson, B.E., te Marvelde, J.G., Hoogeveen, P.G., Hop, W.C., Wheatley, K., Bierings, M.B., Schuurhuis, G.J., de Graaf, S.S., Van Wering, E.R. & van Dongen, J.J. (2010) Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24, 1599-1606.
98. Venditti, A., Maurillo, L., Buccisano, F., Del Poeta, G., Mazzone, C., Tamburini, A., Del Principe, M.I., Consalvo, M.I., De Fabritiis, P., Cudillo, L., Picardi, A., Franchi, A., Lo-Coco, F. & Amadori, S. (2003) Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia, 17, 2178-2182.
99. Walter, R.B., Gooley, T.A., Wood, B.L., Milano, F., Fang, M., Sorror, M.L., Estey, E.H., Salter, A.I., Lansverk, E., Chien, J.W., Gopal, A.K., Appelbaum, F.R. & Pagel, J.M. (2011) Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. Journal of Clinical Oncology, 29, 1190-1197.
100. Wassmann, B., Pfeifer, H., Stadler, M., Bornhauser, M., Bug, G., Scheuring, U.J., Bruck, P., Stelljes, M., Schwerdtfeger, R., Basara, N., Perz, J., Bunjes, D., Ledderose, G., Mahlberg, R., Binckebanck, A., Gschaidmeier, H., Hoelzer, D. & Ottmann, O.G. (2005) Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood, 106, 458-463.
101. Wu, D., Sherwood, A., Fromm, J.R., Winter, S.S., Dunsmore, K.P., Loh, M.L., Greisman, H.A., Sabath, D.E., Wood, B.L. & Robins, H. (2012) High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Science Translational Medicine, 4, 134ra63.
102. Yan, C.H., Liu, D.H., Liu, K.Y., Xu, L.P., Liu, Y.R., Chen, H., Han, W., Wang, Y., Qin, Y.Z. & Huang, X.J. (2012) Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood, 119, 3256-3262.
103. Zeiser, R., Spyridonidis, A., Wasch, R., Ihorst, G., Grullich, C., Bertz, H. & Finke, J. (2005) Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. Leukemia, 19, 814-821.
104. Zhao, X.S., Liu, Y.R., Zhu, H.H., Xu, L.P., Liu, D.H., Liu, K.Y. & Huang, X.J. (2012) Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 91, 183-192.